Determining fracture risk in patients exposed to immune checkpoint inhibitors: the time is now
Open Access
- 22 August 2024
- journal article
- Published by BMJ in BMJ Oncology
- Vol. 3 (1) , e000559
Abstract
Immune checkpoint inhibitors (ICIs) are first-line treatments for melanoma in both the metastatic and adjuvant settings.1 The success of ICIs in the treatment of melanoma is unparallelled yet tempered by the potential development of off-target effects, termed immune-related adverse events (irAEs).2 IrAEs affecting bone and its metabolism, including osteoporosis and fracture, remain infrequently described and poorly understood. Cancer treatment-induced bone loss due to androgen deprivation therapy, aromatase inhibitors and ovarian suppression therapy is well recognised, with established guidelines to assist clinicians in making informed decisions regarding prevention, monitoring and treatment.3 Given the increasing survival associated with ICIs and the potential morbidity and mortality associated with major osteoporotic fractures (MOFs), there is a growing urgency to quantify the potential risk ICIs may pose to bone health and mitigate it if possible.Keywords
This publication has 9 references indexed in Scilit:
- Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitorsBMJ Oncology, 2024
- Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse eventOsteoporosis International, 2023
- Immunoporosis: Role of immune system in the pathophysiology of different types of osteoporosisFrontiers in Endocrinology, 2022
- The Rising Era of “Immunoporosis”: Role of Immune System in the Pathophysiology of OsteoporosisJournal of Inflammation Research, 2022
- Immune-related adverse events and the balancing act of immunotherapyNature Communications, 2022
- Recent Advances in the Treatment of MelanomaNew England Journal of Medicine, 2021
- Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysisInternational Journal of Cancer, 2021
- Bone health in cancer: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2020
- Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case seriesJournal for ImmunoTherapy of Cancer, 2018